

## Constitutive and inducible expression of HLA class II determinants by human osteoblast-like cells in vitro.

H Skjødt, D E Hughes, P R Dobson, R G Russell

*J Clin Invest.* 1990;85(5):1421-1426. <https://doi.org/10.1172/JCI114586>.

### Research Article

Activated immune cells release cytokines which modulate the activity of bone cells in vitro. Expression of major histocompatibility complex (HLA in humans) class II determinants on bone surface cells may be important in local immune cell activation. In this study, expression of HLA-DR and DQ by cultured human bone cells (HBC) derived from normal trabecular bone surfaces was assessed by fluorescence-activated cell sorter (FACS) analysis and immunoperoxidase techniques using monoclonal antibodies. A subset of HBC (10-30%) expressed DR constitutively while 5-15% displayed DQ during long-term culture. HBC lacked a number of monocyte and lymphocyte markers. In addition, both DR+ and DR- HBC (FACS separated) produced osteocalcin stimulated by 1,25-dihydroxyvitamin D<sub>2</sub> (1,25(OH)D<sub>3</sub>). This suggests that both phenotypes belong to the osteoblast lineage. The number of DR+ HBC was increased by interferon-gamma (IFN gamma; 40-95% DR+ cells) whereas DQ+ HBC remained unchanged or was slightly increased (5-20% DQ+ cells). Moreover, 1,25(OH)D<sub>3</sub> enhanced IFN gamma-induced DR expression and at high concentration (10(-7) M) augmented DR expression by itself. Other major osteotropic factors, parathyroid hormone, interleukin 1, and calcitonin, did not affect HBC DR expression. The findings suggest that HBC may participate in activation of the immune system and that some osteotropic factors may regulate this function.

**Find the latest version:**

<https://jci.me/114586/pdf>



# Constitutive and Inducible Expression of HLA Class II Determinants by Human Osteoblast-like Cells In Vitro

Henrik Skjødt,\* David E. Hughes, Pauline R. M. Dobson, and R. Graham G. Russell

\*Departments of Medicine and Pathology, Sundby Hospital, DK-2300 Copenhagen S, Denmark; and Department of Human Metabolism and Clinical Biochemistry, University of Sheffield Medical School, Sheffield S10 2RX, United Kingdom

## Abstract

Activated immune cells release cytokines which modulate the activity of bone cells in vitro. Expression of major histocompatibility complex (HLA in humans) class II determinants on bone surface cells may be important in local immune cell activation. In this study, expression of HLA-DR and DQ by cultured human bone cells (HBC) derived from normal trabecular bone surfaces was assessed by fluorescence-activated cell sorter (FACS) analysis and immunoperoxidase techniques using monoclonal antibodies. A subset of HBC (10–30%) expressed DR constitutively while 5–15% displayed DQ during long-term culture. HBC lacked a number of monocyte and lymphocyte markers. In addition, both DR<sup>+</sup> and DR<sup>-</sup> HBC (FACS separated) produced osteocalcin stimulated by 1,25-dihydroxyvitamin D<sub>2</sub> (1,25(OH)<sub>2</sub>D<sub>3</sub>). This suggests that both phenotypes belong to the osteoblast lineage. The number of DR<sup>+</sup> HBC was increased by interferon-gamma (IFN $\gamma$ ; 40–95% DR<sup>+</sup> cells) whereas DQ<sup>+</sup> HBC remained unchanged or was slightly increased (5–20% DQ<sup>+</sup> cells). Moreover, 1,25(OH)<sub>2</sub>D<sub>3</sub> enhanced IFN $\gamma$ -induced DR expression and at high concentration (10<sup>-7</sup> M) augmented DR expression by itself. Other major osteotropic factors, parathyroid hormone, interleukin 1, and calcitonin, did not affect HBC DR expression. The findings suggest that HBC may participate in activation of the immune system and that some osteotropic factors may regulate this function. (J. Clin. Invest. 1990; 85:1421–1426.) osteoblasts • HLA class II • interferon- $\gamma$  • 1,25-dihydroxyvitamin D<sub>3</sub>

## Introduction

Immune cells including macrophages and lymphocytes present at the bone remodeling site may regulate bone resorption (reviewed by Vaes [1]). For example, interleukin 1 (IL-1) is the major osteoclast-activating cytokine produced by normal activated peripheral blood leukocytes (2). Tumor necrosis factor

This work was presented in part at the First International Workshop on Cells and Cytokines in Bone and Cartilage, Davos, Switzerland, December 1985 and was published as an abstract (1985. *Calcif. Tissue Int.* 38:S28).

Address reprint requests to Dr. Skjødt, Department of Medicine, Sundby Hospital, Italiensvej 1, DK-2300 Copenhagen S, Denmark.

Received for publication 15 September 1989 and in revised form 20 December 1989.

1. Abbreviations used in this paper: EMEM, Eagle's modified MEM; HBC, human bone cell(s); NK, natural killer (cell); TBS, Tris-buffered saline; TNF, tumor necrosis factor.

J. Clin. Invest.

© The American Society for Clinical Investigation, Inc.

0021-9738/90/05/1421/06 \$2.00

Volume 85, May 1990, 1421–1426

alpha (TNF $\alpha$ )<sup>1</sup> produced by macrophages and the T lymphocyte-cytokine tumor necrosis factor-beta (TNF $\beta$ ) also have bone-resorbing activity in vitro (3). These cytokines may stimulate osteoclast precursors (4). In addition, osteoblasts are stimulated by IL-1, TNF $\alpha$ , and TNF $\beta$  to release factors or mediate direct cell-cell membrane interactions activating osteoclastic bone resorption in vitro (5, 6). By contrast, interferon-gamma (IFN $\gamma$ ), released by activated T lymphocytes, inhibits immune cytokine (IL-1, TNF $\alpha$ , and TNF $\beta$ )-stimulated bone resorption in vitro (7). These findings suggest that activated immune cells could be involved in bone resorption by release of cytokines regulating the osteoclast lineage directly and/or through osteoblasts.

Factors that might direct immune cell activation at the remodeling site are unknown. An immune response, however, involves T lymphocyte recognition of antigen displayed on the surface of antigen-presenting cells (APC) in the context of a HLA class II molecule (for a review see Royer and Reinherz [8]). As a consequence of this HLA class II-dependent T cell activation, a number of proteins are synthesized, including osteotropic cytokines (9). Thus, presence of HLA class II-positive cells at the bone remodeling site may be essential for immune cell activation and local release of osteoclast-regulating cytokines.

We examined the expression of HLA class II determinants (DR and DQ) on human osteoblast-like bone cells (HBC) derived from normal trabecular bone surfaces in vitro. Moreover, regulation of HBC HLA class II expression by osteotropic factors were studied, including 1,25(OH)<sub>2</sub>D<sub>3</sub>, parathyroid hormone (PTH), calcitonin, purified human IL-1, and recombinant human IFN $\gamma$  (rIFN $\gamma$ , a known inducer of class II major histocompatibility complex molecules in a variety of immune and nonimmune cells [10]). We demonstrate that (a) a subset of HBC expresses DR and DQ constitutively and (b) HBC DR expression is enhanced by rIFN $\gamma$  and 1,25(OH)<sub>2</sub>D<sub>3</sub>.

## Methods

**Patients.** Bone specimens (surgical discards) were obtained from 20 patients 32–81 yr old (median age 66 yr; 14 female and 6 male) undergoing corrective surgery after fractures or femoral amputation because of vascular insufficiency (representative details of 10 patients in Table I). None of the patients showed signs of bone or joint disease or immune disorders.

**Bone preparation and cell culture.** Human trabecular bone sections were isolated and dissected into 0.3–0.5-cm fragments as described (11). The fragments were washed vigorously in phosphate-buffered saline (PBS, pH 7.4) to remove marrow, seeded onto 9-cm plastic culture dishes (Falcon Labware, Oxford, UK) and cultured in Eagle's modified minimum essential medium (EMEM) containing 10 mM Hepes buffer, 10% fetal calf serum (FCS; heat-inactivated), 2 mM L-glutamine, 50  $\mu$ g/ml ascorbate, 50 U/ml penicillin, and 150  $\mu$ g/ml streptomycin. All cell culture products were from Gibco Laboratories (Paisley, Scotland) and chemicals from Sigma Chemical Co. (Poole, Dorset, UK) unless otherwise stated. Cultures were kept at 37°C in a

Table I. Percentages of HLA-DR- and HLA-DQ-positive HBC from 10 Representative Donors

Donor	Length of culture	DR <sup>+</sup> cells							
		HLA-DR		I2		DAKO-HLA-DR		DQ <sup>+</sup> cells Leu-10	
		FACS	IP	FACS	IP	FACS	IP	FACS	IP
wk		%							
1	5	26	23	23	23	ND	ND	9	8
2	11	14	15	12	13	ND	ND	5	5
3	7	10	ND	13	ND	ND	ND	7	ND
4	21*	24	24	22	21	26	25	15	13
5	14	30	28	25	29	30	29	9	9
6	25*	12	12	14	ND	ND	ND	5	6
7	6	18	19	20	20	16	ND	9	9
8	6	16	ND	ND	ND	ND	ND	8	9
9	13	13	12	18	14	19	18	10	8
10	9	14	14	11	13	16	ND	13	ND

Details of Patients

Donor	Male (M)/female (F)	Age	Diagnosis	Origin of explants
		yr		
1	M	32	Fracture (amputation)	Femoral condyles
2	F	78	Fracture	Femoral head
3	F	69	Fracture	Femoral head
4	M	59	Ischemia (amputation)	Distal tibia
5	F	71	Fracture	Femoral head
6	M	70	Ischemia (amputation)	Femoral condyles
7	F	64	Fracture	Femoral head
8	F	81	Fracture	Femoral head
9	F	62	Fracture	Femoral head
10	F	70	Fracture	Femoral head

First-passage HBC. \* HBC cultures 4 and 6 reexamined at monthly intervals (2–6 mo) showed a stable percentage of DR- and DQ-positive cells (data not shown). IP, immunoperoxidase staining; ND, not determined.

humidified atmosphere of 95% air, 5% CO<sub>2</sub> and after an initial replacement at 24 h, medium was changed once weekly. Cell outgrowth was seen within 7 d and confluent monolayers obtained after 3–6 wk. At confluence, cells were detached by brief exposure (< 5 min at 37°C) to trypsin/EDTA (0.5 and 0.2 g/liter, respectively), replated into 9-cm culture dishes, 3.5-cm multiwell trays, or eight chamber tissue culture glass slides (Lab-Tek Division, Miles Laboratories, Slough, UK) at 5 × 10<sup>3</sup> cells/cm<sup>2</sup>, and cultured in complete EMEM. Viability (eosin exclusion) exceeded 95%. Experiments were commenced 24 h after first passage. All cultures contained cells which expressed an osteoblast-like phenotype in terms of 1,25(OH)<sub>2</sub>D<sub>3</sub>-stimulated osteocalcin production. After exposure to 10<sup>-9</sup> M 1,25(OH)<sub>2</sub>D<sub>3</sub> for 48 h, ≥ 95% of the cells stained positively for osteocalcin using a specific antibody (DAKOPATTS, Glostrup, Denmark) and immunoperoxidase techniques.

**Reagents.** A panel of murine anti-human monoclonal antibodies (MAbs) was used: four MAbs reacting with HLA class II epitopes—HLA-DR and I2 directed at monomorphic DR antigens, Leu-10 reacting with polymorphic DQ epitopes, and DAKO-HLA-DR detecting polymorphic DR and DQ (except DQw10); Leu-M3 detecting cells of the monocyte/macrophage lineage; Leu-1 (pan-T lymphocyte reagent, CD5 [CD, cluster of differentiation antigen]); Leu-14 (B lymphocytes, CD22); and Leu-11 (natural killer [NK] cells, CD16). The MAbs were used in concentrations titrated to be saturating on HBC or positive controls (peripheral blood mononuclear cells). Antibodies were purchased from Becton, Dickinson Ltd., Laboratory Impex,

Middlesex, UK, except DAKO-HLA-DR (DAKOPATTS) and I2 (Coulter Immunology, Hialeah, FL).

Phagocytic activity was determined by addition of latex beads (1.091-μm diameter, Sigma Chemical Co.) to HBC (2 × 10<sup>6</sup> cells in 0.2 ml of EMEM) at a cell/particle ratio of 1:100, sedimentation at 50 g for 5 min (20°C), and incubation at 37°C for 1 h. Cells were then washed three times to remove free latex and examined by phase-contrast microscopy.

Nonspecific esterase staining with alpha-naphthyl butyrate as substrate (12) was performed by means of a Sigma Chemical Co. kit.

In some experiments, cycloheximide (20 μg/ml, Sigma Chemical Co.) was added to HBC cultures to examine the effect of inhibition of protein synthesis on the inducible expression of HLA-DR.

Since reagents might contain low levels of endotoxin, polymyxin B (5 μg/ml, Sigma Chemical Co.) was added in some experiments to evaluate the effect of endotoxin inhibition (13).

**Effect of osteotropic factors on HBC HLA class II expression.** Human rIFNγ (Amgen Co., Thousand Oaks, CA 91320; kindly provided by Dr. R. C. Rees, Department of Virology, University of Sheffield Medical School), human purified IL-1 (Lot N101; a generous gift of Dr. C. A. Dinarello, New England Medical Center, Boston, MA), 1,25(OH)<sub>2</sub>D<sub>3</sub> (kindly supplied by Dr. M. R. Uskovics, Hoffman La-Roche Co., Nutley, NJ), purified bovine PTH 1-84 fragment (from the National Institutes for Biological Standards and Control, South Mimms, UK), and salmon calcitonin (obtained from Armour Pharmaceutical Co., East Sussex, UK) were added to cultures (duplicate

3.5-cm multiwells or chamber slides) for 48 h. During experiments medium was changed daily. After culture, 3.5-cm wells were trypsinized, washed three times (EMEM, 4°C), kept in suspension by gentle stirring in EMEM with 1% bovine serum albumin (BSA) for 4–6 h (at 37°C in a 95% air, 5% CO<sub>2</sub> incubator), and then aliquotted at 5 × 10<sup>5</sup> cells per sample for fluorescence-activated cell sorter (FACS) analysis. Chamber slides were examined also by immunoperoxidase staining.

**FACS analysis.** All reagents were diluted in EMEM with 0.1% BSA and 0.02% sodium azide. For indirect immunofluorescence, saturating concentrations of the desired MAb were added to HBC (5 × 10<sup>5</sup> cells incubated at 4°C for 30 min). Controls were stained with an isotype-specific MAb of irrelevant specificity. After washing twice in PBS, fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse IgG (Tago Inc., Tissue Culture Service, Slough, Berkshire, UK) was added as a second layer (30 min, 4°C). The cells were then washed three times in PBS and kept on ice in a PBS/0.1% BSA solution. Immediately before analysis, samples were agitated and gently passed through a 27-gauge needle to avoid settling and aggregation. A FACS 420 (Becton, Dickinson Ltd.) was used for analysis of fluorescent cells (14) based on a reading of 10,000 viable cells per sample gated on the basis of propidium iodide exclusion (viability > 95%). Percent positive cells was calculated by integration of area under the curve upon subtraction of the respective control background. The mean fluorescence intensity was measured by the median channel. In all experiments, a constant setting of the FACS (gain, amplifier, and photomultiplier voltage) was maintained. Membrane marker-positive cells were evaluated in parallel with fluorescence microscopy and immunoperoxidase staining.

**Immunoperoxidase staining.** After washing in PBS, HBC duplicate chamber slide cultures were fixed for 30 s in a phosphate-buffered acetone/formaldehyde fixative. Slides were rinsed in 0.2 M Tris-buffered saline (TBS), pH 7.6, and air-dried. To inactivate any endogenous peroxidase activity slides were treated with 3% H<sub>2</sub>O<sub>2</sub> in TBS for 5 min at room temperature and rinsed well with buffer. Nonimmune rabbit serum (10%, Wellcome, Kent, UK) in PBS was added, and slides were incubated for 20 min at room temperature. The rabbit serum was tapped off and then, without rinsing, 20 µl of MAb, titrated to establish a low concentration still effective for staining, was added in a TBS/0.1% BSA solution, and slides were incubated for 30 min at room temperature followed by a wash in TBS. Peroxidase-conjugated rabbit anti-mouse IgG (DAKOPATTS; 20 µl diluted 1:50 in TBS/0.1% BSA) was added, slides were incubated for 30 min at room temperature, and rinsed with TBS. Finally, 20 µl of a 3:3 diamino-benzidine (Sigma Chemical Co., grade II) solution (6 mg in 10 ml of 0.2 M Tris buffer, pH 7.6, containing 0.1% hydrogen peroxide) was added, and slides were incubated for 10 min at room temperature, rinsed, hematoxylin-counterstained, and mounted with coverslips. In all experiments, > 400 cells were counted for each duplicate sample.

**Cell sorting.** HBC were sorted on the basis of HLA-DR epitope density. Samples of 2 × 10<sup>7</sup> cells were detached from 9-cm plates (1–2 × 10<sup>6</sup> cells per plate) and prepared for indirect immunofluorescence using the MAb HLA-DR. Using the FACS 420 under sterile conditions, cells were separated into a cell fraction with high-density DR epitope expression (cutoff point was chosen at fluorescence intensity channel 60, gating channel 61–254; > 95% DR<sup>+</sup>), and a cell fraction with low-density DR expression (gating channel 1–60; < 5% DR<sup>+</sup>). After sorting, the recovered cell populations were washed twice, plated into 3.5-cm multiwell trays at 5 × 10<sup>3</sup> cells/cm<sup>2</sup>, and cultured in complete EMEM. The purity of the sorted cells was determined by reanalysing aliquots of the sorted subsets on the FACS 420 immediately after sorting. After a 48-h recovery period the cells were assayed for 1,25(OH)<sub>2</sub>D<sub>3</sub>-stimulated osteocalcin production.


**Assay of osteocalcin.** Osteocalcin was measured by radioimmunoassay as described previously (11). The antibody used was raised in rabbits to purified osteocalcin isolated from calf bone.

**Statistical analysis.** Significant differences were compared by Student's *t* test. Data are expressed as the average of replicates (mean ± SEM).

## Results

**HBC express HLA-DR and DQ constitutively in long-term culture.** Examined at first passage, HBC had the appearance of homogeneous elongated, generally bipolar, adherent fibroblast-like cells. When HBC were studied by using anti-HLA-DR and -DQ MAbs, many cells showed a stable expression of these HLA class II determinants even after several months of culture. Table I shows the percentage of HBC positive for the various anti-HLA class II reagents in 10 representative cultures. No difference was found between results using monomorphic and polymorphic anti-DR MAbs. The mean values for all cultures (*n* = 20) were 15.2% DR<sup>+</sup> (MAb HLA-DR) HBC (range 10–30%) and 8.5% DQ<sup>+</sup> (MAb Leu-10) HBC (range 5–15%). The possibility that the trypsin/EDTA treatment necessary for preparation of single cell suspensions for FACS analysis might change HLA class II expression was excluded (Table I shows no significant differences between cells stained on chamber slides without enzymatic treatment [immunoperoxidase] and the stained single cell suspension [FACS]). In all cultures, DR<sup>+</sup> HBC exceeded DQ<sup>+</sup> HBC in terms of cells numbers and staining intensity as documented by FACS analysis (Fig. 1 illustrates results from two representative cultures). To evaluate the effect of endotoxin that might contaminate reagents, polymyxin B was added into two cultures with and without bacterial LPS (0.5 µg/ml, Sigma Chemical Co.) for a 48-h incubation period. No change of HLA-DR and -DQ expression was found (data not shown).

**HBC lack a panel of immune cell markers.** Since hemopoietic marrow cells, such as monocyte/macrophages and lymphocytes, might be present in the HBC cultures possibly affecting HLA class II expression, some immune cell markers were examined (Table II). None of the cells showed phagocytic activity as determined by latex ingestion. A faint staining for nonspecific esterase in all HBC (previously described in a similar cell system [15]) contrasted with the bright membrane



**Figure 1.** FACS analysis illustrating the distribution of HLA-DR- and HLA-DQ-positive HBC from two donors. (Black area) Background staining with MAb of irrelevant specificity; (curve) DR- and DQ-positive cells. HLA-DR, MAb HLA-DR; Leu-10, MAb Leu-10.

Table II. HBC Examined for Immune Cell Markers

Marker	Positive cells	n
	%	
<b>Mφ</b>		
α-Naphthyl butyrate esterase	100 (weak staining)	9
Latex ingestion	0	8
MAb Leu-M3	0	15
<b>T lymphocytes</b>		
MAb Leu-1 (CD5)	0	15
<b>B lymphocytes</b>		
MAb Leu-14 (CD22)	0	15
<b>NK cells</b>		
MAb Leu-11 (CD16)	0	15

First-passage HBC. n, number of cultures analyzed; MAb staining assessed by FACS analysis, immunofluorescence microscopy, and immunoperoxidase microscopy; CD, cluster of differentiation.

staining of peripheral blood monocytes. In addition, membrane markers of monocyte/macrophages, T and B lymphocytes, and NK cells determined by using MAbs were negative.

**Sorted DR<sup>+</sup> and DR<sup>-</sup> HBC both produce osteocalcin.** In order to investigate the possible presence of an osteoblast marker, osteocalcin (16), on the DR<sup>+</sup> and DR<sup>-</sup> subsets, HBC were separated into two fractions on the basis of HLA-DR antigen density by FACS. The HLA-DR<sup>+</sup> fraction was defined as strongly positive fluorescence intensity (channel 61-254; MAb HLA-DR, > 95% DR<sup>+</sup>). A typical FACS histogram of pre- and postsort HLA-DR expression is shown in Fig. 2. Although 0-9% DR<sup>+</sup> cells were present immediately after sort in the low-density DR fraction, these cells diminished after replating (after 48 h of culture 0-2% DR<sup>+</sup> cells remained in the DR<sup>-</sup> fraction). Neither conditioned medium from the presort HBC or postsort DR<sup>+</sup> fraction added to the DR<sup>-</sup> fraction nor conditioned medium from the presort HBC or postsort DR<sup>-</sup>




Figure 2. Separation of HBC into high- and low-density HLA-DR-positive cells. A, presort fluorescent histogram of HLA-DR using the MAb HLA-DR (23% of cells are positive); B, postsort reanalysis of low-density DR fraction. Although initially DR<sup>+</sup> cells were left in fraction B (range of 0-9% in all cultures determined) these cells were undetectable within 48-72 h. C, postsort reanalysis of high-density DR-positive cells (99% DR<sup>+</sup>).

fraction added to the DR<sup>+</sup> fraction altered DR expression in cultures (examined after 1 wk of postsort culture; data not shown). Both DR<sup>+</sup> and DR<sup>-</sup> cultures showed viability > 95% (eosin exclusion) after 1 wk of postsort culture. Whereas remaining DR<sup>+</sup> cells in the low-density postsort populations rapidly disappeared within 48 h as detected by immunoperoxidase staining, the percentage of DR<sup>+</sup> cells, having remained stable for at least 1 wk, gradually diminished in the high-density postsort culture after 2-4 wk (a range of 5-40% reduction in numbers of DR<sup>+</sup> cells). In addition, the high-density populations showed signs of increasing cell death after 4-6 wk in culture. By contrast, the low-density population remained stable in long-term culture without reappearance of DR<sup>+</sup> cells when reexamined after 2-4 wk. Nevertheless, reappearance of DR-expressing HBC in these populations at a later stage has not been determined.

A total of four experiments on osteocalcin production by different pre- and postsort HBC populations were undertaken. Fig. 3 illustrates one representative experiment. Osteocalcin was produced by 1,25(OH)<sub>2</sub>D<sub>3</sub>-stimulated unseparated HBC as previously reported (11). Both DR<sup>+</sup> and DR<sup>-</sup> sorted HBC produced osteocalcin in a dose-dependent manner when stimulated by 1,25(OH)<sub>2</sub>D<sub>3</sub> 48 h and similarly 1 wk after cell separation. In the DR<sup>+</sup> populations HLA-DR and osteocalcin were coexpressed since they were both present in ≥ 95% of the cells (data not shown).

**rIFNγ and 1,25(OH)<sub>2</sub>D<sub>3</sub> stimulate HBC HLA class II expression, whereas IL-1, PTH, and calcitonin have no effect alone or with rIFNγ.** To test the influence of osteotropic hormonal factors on HBC HLA-DR and DQ expression six experiments on different HBC cultures were undertaken. In Table III results of 48-h HBC stimulation by (a) rIFNγ and (b) 1,25(OH)<sub>2</sub>D<sub>3</sub>, PTH, IL-1, and calcitonin with and without rIFNγ from two representative experiments are presented. DR expression was assessed in all cases; DQ expression was determined after rIFNγ stimulation only. The enhancement of DR expression by rIFNγ (10 U/ml; DR<sup>+</sup> HBC range 40-90%, DQ<sup>+</sup> HBC range 5-20%) and 1,25(OH)<sub>2</sub>D<sub>3</sub> (10<sup>-7</sup> M; DR<sup>+</sup> HBC range 24-50%) was blocked by cycloheximide (Table III) suggesting that new protein synthesis was necessary for this alter-




Figure 3. Changes in osteocalcin production (ordinate; ng/ml) into the medium by first-passage unseparated HBC (●), FACS-separated HLA-DR<sup>+</sup> (99% DR<sup>+</sup>) HBC (▲), and FACS-separated HLA-DR<sup>-</sup> (0% DR<sup>+</sup>) HBC (■) in response to 48 h of treatment with 1,25(OH)<sub>2</sub>D<sub>3</sub> (abscissa; M). The stippled area represents the mean ± SEM of control. n = 6; control, cultures without addition of 1,25(OH)<sub>2</sub>D<sub>3</sub>.

Table III. Effects of Osteotropic Factors on HBC HLA-DR and HLA-DQ Expression

Addition	DR <sup>+</sup> HBC		DQ <sup>+</sup> HBC	
	Exp. 1	Exp. 2	Exp. 1	Exp. 2
	%		%	
Medium alone	16±4	26±2	7±1	11±3
rIFN $\gamma$ (U/ml)				
0.1				
1	49±5*	67±8*	6±1	17±5
10	77±11*	69±9*	6±2	20±1*
1,000	72±8*	81±15*	9±5	20±6
10 + cycloheximide	80±11*	ND	6±0	ND
20 $\mu$ g/ml	19±5	29±6	5±0	13±4
	DR <sup>+</sup> HBC			
	Without rIFN $\gamma$		With rIFN $\gamma$ (10 U/ml)	
Addition	Exp. 1	Exp. 2	Exp. 1	Exp. 2
	%			
1,25(OH) <sub>2</sub> D <sub>3</sub> (M)				
10 <sup>-10</sup>				
10 <sup>-9</sup>	14±4	28±3	73±5	79±9
10 <sup>-8</sup>	19±4	33±8	90±3 <sup>‡</sup>	88±1 <sup>‡</sup>
10 <sup>-7</sup>	26±7	ND	95±4 <sup>‡</sup>	ND
10 <sup>-7</sup> + cycloheximide (20 $\mu$ g/ml)	45±4 <sup>‡</sup>	49±2 <sup>‡</sup>	93±6 <sup>‡</sup>	90±3 <sup>‡</sup>
PTH (M)				
10 <sup>-9</sup>	17±2	ND	75±7	ND
10 <sup>-8</sup>	16±5	29±5	70±7	66±5
10 <sup>-7</sup>	16±4	23±2	77±2	72±9
IL-1 (U/ml)				
5	19±7	22±5	69±3	65±13
50	16±2	27±5	77±11	69±3
Calcitonin (M)				
10 <sup>-9</sup>	20±4	26±2	74±2	70±4
10 <sup>-8</sup>	17±2	22±5	76±2	69±1

FACS analysis of first-passage HBC after incubation for 48 h with appropriate osteotropic factor(s). Results expressed as mean of triplicate  $\pm$  SEM.

\* Significantly different from control (medium alone),  $P < 0.05$ .

<sup>‡</sup> Significantly different from control (rIFN $\gamma$  alone),  $P < 0.05$ .

ND, not determined.

ation. In all experiments, 1,25(OH)<sub>2</sub>D<sub>3</sub> (10<sup>-9</sup> to 10<sup>-7</sup> M) enhanced the rIFN $\gamma$ -stimulated DR mean fluorescence intensity (data not shown). When added to postsort high- and low-density DR HBC populations, IFN $\gamma$  enhanced DR expression in both systems, indicating a stimulatory action on both DR<sup>+</sup> as well as DR<sup>-</sup> HBC (data not shown).

## Discussion

The demonstration of a constitutive, stable expression of HLA class II determinants by cells derived from normal trabecular bone surfaces and kept in long-term culture suggests the possi-

bility of an in situ phenomenon. However, soluble factors in the culture medium that might alter HBC HLA-DR expression were not found in conditioned media from either unseparated HBC or DR<sup>+</sup> and DR<sup>-</sup> separated fractions. Although expression of class II antigens by 29–46% of isolated normal rabbit chondrocytes has been reported (17), normal human connective tissue cells do not express HLA class II antigens constitutively, including human fibroblasts (18) and human chondrocytes (19). This raised the question whether HLA class II-positive marrow hemopoietic cells might be present in our human bone cell cultures. However, this appears unlikely since morphologically HBC were homogeneous and fibroblast-like, and HBC lacked monocyte/macrophage-, pan-T and B lymphocyte, and NK cell markers. In addition, separated DR<sup>+</sup> and DR<sup>-</sup> HBC both produced the bone protein, osteocalcin, when stimulated by 1,25(OH)<sub>2</sub>D<sub>3</sub>. So far, osteocalcin has been reported to be produced by osteoblasts only (16), suggesting an osteoblast-like phenotype of DR<sup>+</sup> as well as DR<sup>-</sup> HBC. Nevertheless, the presence in our cultures of dendritic cells which express high levels of both HLA-DR and -DQ (20) has not been excluded.

The separated high- and low-density DR-expressing populations did not revert back to the original distribution after 4 wk of postsort culture. On the contrary, the DR<sup>+</sup> subset rapidly disappeared from the low-density fraction and after 2 wks were reduced in the high-density fraction. Possibly, the DR<sup>+</sup> subset may be more fragile than their DR<sup>-</sup> counterpart and thus damaged selectively during the FACS procedures. Alternatively, the DR<sup>+</sup> phenotype may depend upon factors expressed within the unseparated population only.

The observation that IFN $\gamma$  stimulates HBC HLA-DR expression is in accordance with data on other connective tissue cells including human dermal fibroblasts (18), human synovial fibroblasts (21), and human chondrocytes (19). Although IFN $\gamma$  induces HLA-DQ in certain cells including monocytes (22), this cytokine has been reported to induce only low levels or no HLA-DQ determinants on connective tissue cells such as synovial fibroblasts (23), chondrocytes (19), and, as in this study, HBC.

In contrast with two other major bone resorbing factors, PTH (10<sup>-9</sup> to 10<sup>-7</sup> M) and IL-1 (5–50 U/ml), 1,25(OH)<sub>2</sub>D<sub>3</sub> (10<sup>-9</sup> to 10<sup>-7</sup> M) enhanced IFN $\gamma$ -stimulated HBC HLA-DR expression and at high supraphysiological levels (10<sup>-7</sup> M) stimulated DR expression by itself. Similar findings have been reported regarding the Ia-negative murine myelomonocytic cell line WEHI-3 (24). In this study 1,25(OH)<sub>2</sub>D<sub>3</sub> (10<sup>-10</sup> to 10<sup>-8</sup> M) was found to enhance IFN $\gamma$ -induced Ia expression. By contrast, using a HLA class II-positive melanoma cell line, Carrington et al. (25) found a dose-dependent inhibition of DR $\alpha$  mRNA by 1,25(OH)<sub>2</sub>D<sub>3</sub> (10<sup>-12</sup> to 10<sup>-8</sup> M). In other class II-positive cell lines, however, class II molecules were not altered by 1,25(OH)<sub>2</sub>D<sub>3</sub> (26). Factors affecting class II expression in opposite directions, released during 1,25(OH)<sub>2</sub>D<sub>3</sub> stimulation, might explain the differences between the cell lines. Thus, 1,25(OH)<sub>2</sub>D<sub>3</sub> has been reported to stimulate production of IFN $\gamma$  by T lymphocytes in vitro (26). To test the possibilities that 1,25(OH)<sub>2</sub>D<sub>3</sub> (a) stimulates factors, such as IFN $\gamma$ , which induce class II expression in the HBC cultures and/or (b) enhances the responsiveness of HBC to IFN $\gamma$  by altering HBC proliferation, further studies are needed. Calcitonin, which inhibits the bone-resorbing activity of osteoclasts (27) and also may affect osteoblasts (28), did not alter HBC DR expression

( $10^{-9}$  to  $10^{-8}$  M) suggesting that a change in HBC DR levels is not involved in calcitonin-mediated osteoclast inhibition.

We suggest that HLA class II-positive bone surface cells of the osteoblast lineage may play a role in local T lymphocyte activation including release of osteoclast-activating T lymphocyte-derived cytokines. Thus, studies are in progress on the abilities of HBC to stimulate in mixed lymphocyte reaction (MLR) and to present antigen (29). Since the presence of IL-1 may be important for these activities the recent finding of constitutive IL-1 production by HBC (30) is of interest. Enhancement of HBC HLA class II expression by IFN $\gamma$  and 1,25(OH) $_2$ D $_3$  could be involved in the osteotropic activity of these factors.

## Acknowledgments

We thank Mr. J. Lowry and Mr. C. Day for expert technical assistance.

We are grateful to the following for financial support: The British Council; Glaxo Group Research, Greenford, U.K.; and the Danish Rheumatism Association (Gigtforeningen).

## References

1. Vaes, G. 1988. Cellular biology and biochemical mechanism of bone resorption. *Clin. Orthop. Relat. Res.* 231:239-271.
2. Dewhirst, F. E., P. P. Stashenko, J. E. Mole, and T. Tsurumachi. 1985. Purification and partial sequence of human osteoclast-activating factor: identity with interleukin 1 $\beta$ . *J. Immunol.* 135:2562-2568.
3. Bertolini, D. R., G. E. Nedwin, T. S. Bringman, D. D. Smith, and G. R. Mundy. 1986. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumor necrosis factors. *Nature (Lond.)* 319:516-519.
4. Roodman G. D., N. Takahashi, A. Bird, and G. R. Mundy. 1987. Tumor necrosis factor alpha (TNF) stimulates formation of osteoclast-like cells (OCL) in long term human bone marrow cultures by stimulating production of interleukin-1 (IL-1). *Clin. Res.* 35:515a. (Abstr.)
5. Thomson, B. M., J. Saklatvala, and T. J. Chambers. 1986. Osteoblasts mediate interleukin 1 stimulation of bone resorption by rat osteoclasts. *J. Exp. Med.* 164:104-111.
6. Thomson, B. M., G. R. Mundy, and T. J. Chambers. 1987. Tumor necrosis factor  $\alpha$  and  $\beta$  induce osteoblastic cells to stimulate osteoclastic bone resorption. *J. Immunol.* 138:775-779.
7. Gowen, M., G. E. Nedwin, and G. R. Mundy. 1986. Preferential inhibition of cytokine-stimulated bone resorption by recombinant interferon gamma. *J. Bone Miner. Res.* 1:469-473.
8. Royer, H. D., and E. L. Reinherz. 1987. T lymphocytes: Ontogeny, function, and relevance to clinical disorders. *N. Engl. J. Med.* 317:1136-1142.
9. Dinarello, C. A., and J. W. Mier. 1987. Lymphokines. *N. Engl. J. Med.* 317:939-945.
10. Rose, M. L. 1985. Immunoregulation of MHC antigen expression. *Immunol. Today.* 6:297-298.
11. Beresford, J. N., J. A. Gallagher, J. W. Poser, and R. G. G. Russell. 1984. Production of osteocalcin by human bone cells in vitro: effects of 1,25(OH) $_2$ D $_3$ , 24,25(OH) $_2$ D $_3$ , PTH and glucocorticoids. *Metab. Bone Dis. Relat. Res.* 5:229-235.
12. Bozdech, M. J., and D. F. Bainton. 1981. Identification of  $\alpha$ -naphthyl butyrate esterase as a plasma membrane ectoenzyme of monocytes and as a discrete intracellular membrane-bounded organelle in lymphocytes. *J. Exp. Med.* 153:182-195.
13. Jacobs, D. M., and D. C. Morrison. 1977. Inhibition of the mitogenic response to lipopolysaccharide (LPS) in mouse spleen cells by polymyxin B. *J. Immunol.* 118:21-25.
14. Horan, P. K., and M. R. Loken. 1985. A practical guide for the use of flow systems. In *Flow Cytometry: Instrumentation and Data Analysis*. M. A. van Dilla, P. N. Dean, O. D. Laerum, and M. R. Melamed, editors. Academic Press, Inc., New York. 259-288.
15. Ashton, B. A., F. Abdullah, J. Cave, M. Williamson, B. C. Sykes, M. Couch, and J. W. Poser. 1985. Characterization of cells with high alkaline phosphatase activity derived from human bone and marrow: preliminary assessment of their osteogenicity. *Bone* 6:313-319.
16. Price, P. A. 1983. Osteocalcin. In *Bone and Mineral Research Annual. Volume 1*. W. A. Peck, editor. Excerpta Medica, Amsterdam. 157-190.
17. Tiku, M. L., S. Liu, C. W. Weaver, M. Teodorescu, and J. L. Skosey. 1985. Class II histocompatibility antigen-mediated immunologic function of normal articular chondrocytes. *J. Immunol.* 135:2923-2928.
18. Geppert, T. D., and P. E. Lipsky. 1985. Antigen presentation by interferon- $\gamma$ -treated endothelial cells and fibroblasts: differential ability to function as antigen-presenting cells despite comparable Ia expression. *J. Immunol.* 135:3750-3762.
19. Jahn, B., G. R. Burmester, H. Schmid, G. Weseloh, P. Rohwer, and J. R. Kalden. 1987. Changes in cell surface antigen expression on human articular chondrocytes induced by gamma-interferon. *Arthritis Rheum.* 30:64-74.
20. Knight, S. C., P. Fryer, S. Griffith, and B. Harding. 1987. Class II histocompatibility antigens on human dendritic cells. *Immunology*. 61:21-24.
21. Amento, E. P., A. K. Bhan, K. G. McCullagh, and S. M. Krane. 1985. Influence of gamma interferon on synovial fibroblast-like cells. Ia induction and inhibition of collagen synthesis. *J. Clin. Invest.* 76:837-848.
22. Gonwa, T. A., and J. D. Stobo. 1984. Differential expression of Ia molecules by human monocytes. *J. Clin. Invest.* 74:859-866.
23. Burmester, G. R., B. Jahn, P. Rohwer, J. Zacher, R. J. Winchester, and J. R. Kalden. 1987. Differential expression of Ia antigens by rheumatoid synovial lining cells. *J. Clin. Invest.* 80:595-694.
24. Morel, P. A., S. C. Manolagas, D. M. Provvedini, D. R. Wegmann, and J. M. Chiller. 1986. Interferon- $\gamma$ -induced Ia expression in WEHI-3 cells is enhanced by the presence of 1,25-dihydroxyvitamin D $_3$ . *J. Immunol.* 136:2181-2186.
25. Carrington, M. N., B. Tharp-Hiltbold, J. Knoth, and F. E. Ward. 1988. 1,25-dihydroxyvitamin D $_3$  decreases expression of HLA class II molecules in a melanoma cell line. *J. Immunol.* 140:4013-4018.
26. Manolagas, S. C., D. M. Provvedini, D. J. Young, and C. D. Tsoukas. 1988. At physiological concentrations 1,25-dihydroxyvitamin D $_3$  acts directly on T cells to stimulate  $\gamma$ -interferon. *J. Bone Miner. Res.* 3:S82. (Abstr.)
27. Friedman, J., and L. G. Raisz. 1965. Thyrocalcitonin: inhibitor of bone resorption in tissue culture. *Science (Wash. DC)*. 150:1465-1467.
28. Farley, J., N. M. Tarboux, S. L. Hall, T. A. Linkhart, and D. J. Baylink. 1988. The anti-bone-resorptive agent calcitonin also acts in vitro to directly increase bone formation and bone cell proliferation. *Endocrinology*. 123:159-167.
29. Skjødt, H., T. Møller, and S. Freiesleben. 1989. Human osteoblast-like cells expressing MHC class II determinants stimulate allogeneic and autologous peripheral blood mononuclear cells and function as antigen presenting cells. *Immunology*. 68:416-420.
30. Hughes, D. E., M. Gowen, R. G. G. Russell. 1988. Interleukin 1 as a paracrine factor in bone: Effects on osteoclast-like cell formation and production by osteoblast-like cells. *J. Bone Miner. Res.* 3:S196. (Abstr.)